Development of human endogenous retrovirus type K- related treatments for human diseases.
J Med Virol
; 96(3): e29532, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38497450
ABSTRACT
Human endogenous retroviruses (HERVs) constitute approximately 8% of the human genome and have long been regarded as silent passengers within our genomes. However, the reactivation of HERVs has been increasingly linked to a range of human diseases, particularly the HERV-K (HML-2) family. Many studies are dedicated to elucidating the potential role of HERV-K in pathogenicity. While the underlying mechanisms require further investigation, targeting HERV-K transactivation emerges as a promising avenue for treating human diseases, including cancer, autoimmune disorders, neurodegenerative conditions, and infectious diseases. In this review, we summarize recent advancements in the development of HERV-K-targeted therapeutic strategies against various human diseases, including antiretroviral drugs, immunotherapy, and vaccines.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Terapia Biológica
/
Retrovirus Endógenos
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article